RxDoctor Payments Data

Linda Nguyen, MD

Gastroenterology · Stanford, CANPI 1750303152

Payments from drug & device makers

$257,530in general payments, 2019–2025

Across 179 payments — averaging $1438.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$102K
  • Enterra Medical, Inc.$33K
  • Eli Lilly$25K
  • Vanda Pharmaceuticals Inc.$23K
  • Evoke Pharma, Inc.$19K
  • Phathom Pharmaceuticals, Inc.$17K
  • plus $38K from 16 others

What the payments were for

  • Consulting fees$72,17354%
  • Speaking & faculty fees$45,49334%
  • Travel & lodging$6,3025%
  • Food & beverage$8,7667%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$257,530 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$84,149
Medicare patients
328
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide115$116,274
MotegrityPrucalopride Succinate67$81,324
CreonLipase/Protease/Amylase34$73,461
Dexlansoprazole DrDexlansoprazole44$15,742
TrulancePlecanatide14$13,978
MovantikNaloxegol Oxalate19$10,204
VoqueznaVonoprazan Fumarate14$8,969
Cromolyn Sodium29$8,063
Lubiprostone45$4,617
Sucralfate47$3,417
Pyridostigmine Bromide61$3,368
ClinisolParenteral Amino Acid 15% No.515$3,200
Scopolamine11$2,360
Dicyclomine Hcl52$2,180
SmoflipidFat Emul/Soy/Mct/Oliv/Fish Oil43$2,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$102,023$189,734149 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$3,241$81,32467 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$7,502$13,97814 claims
Phathom Pharmaceuticals, Inc.Voquezna$17,034$8,96914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →